Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia

Authors

  • A. Gradíssimo Oliveira,

    Corresponding author
    1. National Reference Laboratory of STI for Human Papillomavirus and Genital Herpes Virus, Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal
    • Corresponding author: A. Gradíssimo Oliveira, Departamento de Doenças Infecciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge I.P., Av. Padre Cruz, 1649-016 Lisboa, Portugal

      E-mail: ana.oliveira@insa.min-saude.pt.

    Search for more papers by this author
    • These authors contributed equally to this work.
  • C. Delgado,

    1. Department of Bioinformatics and Computational Biology, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal
    Search for more papers by this author
    • These authors contributed equally to this work.
  • N. Verdasca,

    1. National Reference Laboratory of STI for Human Papillomavirus and Genital Herpes Virus, Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal
    Search for more papers by this author
  • Â. Pista

    1. Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal
    Search for more papers by this author

Abstract

The aim of this work was to assess the value of the physical status of human papillomavirus (HPV) DNA as a disease marker for cervical cancer development in a set of 248 DNA samples previously genotyped as HPV 16 or 18, by calculating the E2/E6 ratio through real-time PCR. There was a significant difference in integration status according to disease grade for both genotypes (p <0.001). Furthermore, especially for HPV 18, determining the DNA physical status could be a useful biomarker in predicting cervical cancer risk development, with a lower E2/E6 ratio clinically associated with the development of a precancerous lesion.

Ancillary